Anebulo Pharmaceuticals (ANEB) Change in Accured Expenses (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Change in Accured Expenses of $574502.0 for Q4 2025, up 137.2% year-over-year from $242201.0 in Q4 2024, and up 519.28% quarter-over-quarter from $92769.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Change in Accured Expenses for 6 consecutive years, with $574502.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 137.2% year-over-year to $574502.0; the TTM figure through Dec 2025 stood at $371500.0 (up 373.98% YoY), while the FY2025 annual figure was $159356.0, up 137.05% from the prior year.
- Change in Accured Expenses climbed to $574502.0 in Q4 2025 per ANEB's latest filing, from $92769.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $851141.0 in Q4 2022 and bottomed at -$521244.0 in Q2 2024.
- Historically, Change in Accured Expenses has averaged $43541.9 across 5 years, with a median of $19251.5 in 2022.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 896.3% — and 2023, when it tumbled 2248.09%.
- Anebulo Pharmaceuticals' Change in Accured Expenses stood at -$106887.0 in 2021, then surged by 896.3% to $851141.0 in 2022, then plunged by 36.05% to $544266.0 in 2023, then tumbled by 55.5% to $242201.0 in 2024, then jumped by 137.2% to $574502.0 in 2025.
- Business Quant data shows ANEB's Change in Accured Expenses at $574502.0 in Q4 2025, $92769.0 in Q3 2025, and $145059.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 574,502.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 574,502.00 |
| Dec 31, 2025 | 574,502.00 |
| Sep 30, 2025 | 92,769.00 |
| Sep 30, 2025 | 92,769.00 |
| Jun 30, 2025 | 145,059.00 |
| Jun 30, 2025 | 145,059.00 |
| Mar 31, 2025 | -440,830.00 |
| Mar 31, 2025 | -440,830.00 |
| Dec 31, 2024 | 242,201.00 |
| Dec 31, 2024 | 242,201.00 |
| Sep 30, 2024 | 212,926.00 |
| Sep 30, 2024 | 212,926.00 |
| Jun 30, 2024 | -521,244.00 |
| Jun 30, 2024 | -521,244.00 |
| Mar 31, 2024 | -69,476.00 |
| Mar 31, 2024 | -69,476.00 |
| Dec 31, 2023 | 544,266.00 |
| Dec 31, 2023 | 544,266.00 |
| Sep 30, 2023 | -383,645.00 |
| Sep 30, 2023 | -383,645.00 |